Compare BHK & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHK | REPL |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 679.6M | 721.7M |
| IPO Year | N/A | 2018 |
| Metric | BHK | REPL |
|---|---|---|
| Price | $9.49 | $9.95 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 188.3K | ★ 1.7M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 8.34% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.02 | $2.68 |
| 52 Week High | $11.09 | $14.80 |
| Indicator | BHK | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 41.99 | 57.76 |
| Support Level | $9.45 | $9.63 |
| Resistance Level | $9.56 | $10.29 |
| Average True Range (ATR) | 0.07 | 0.59 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 23.08 | 35.68 |
Blackrock Core Bond Trust is a closed-ended management investment company. Its objective is to provide current income and capital appreciation. The trust seeks to achieve its investment objective by investing a majority of its managed assets in bonds that are investment-grade quality at the time of investment. The trust's investments will include a broad range of bonds, including corporate bonds, U.S. government and agency securities and mortgage-related securities.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.